Goldman Sachs Group Inc Annovis Bio, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
975KCall Options Held
647KPut Options Held
1.58M-
Vanguard Group Inc Valley Forge, PA361KShares$2.93 Million0.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$815,7420.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA100KShares$810,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA76.2KShares$617,4870.0% of portfolio
-
Wescott Financial Advisory Group, LLC41.6KShares$337,0160.03% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $66.1M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...